Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
Some research suggests that whole-plant cannabis compounds (like THC, CBD, other cannabinoids, terpenes, and flavonoids) can interact so the plant’s effects differ from CBD alone. Healthline explains three CBD types — full-spectrum, broad-spectrum, and isolate — and notes legal, safety, and labeling limits. The article says there is evidence for…
This laboratory study found that cannabidiol (CBD), a non‑psychoactive compound from Cannabis sativa, reduced fat production and inflammation in human sebaceous (oil) gland cells. The effects were seen in cultured human sebocytes and in human skin organ cultures, where CBD blocked the fat‑making (lipogenic) actions of several compounds. These results…
This is a short 1970 Nature paper by E. W. Gill, W. D. Paton and R. G. Pertwee that reports preliminary experiments on the chemistry and pharmacology of cannabis. The PubMed entry has no abstract, but its indexing shows the paper looked at drug effects and toxicity, and at topics…
Researchers isolated a new natural cannabis compound called Δ9-tetrahydrocannabiphorol (Δ9-THCP) and its CBD counterpart (CBDP). In lab tests, Δ9-THCP bound very strongly to the human CB1 receptor (Ki = 1.2 nM) and caused THC-like effects in mice (less movement, pain relief, catalepsy, and lower body temperature). The authors say Δ9-THCP…
This 2024 literature review examined lab, animal, and human studies on cannabidiol (CBD) for skin and cosmetic use. It says CBD is a non‑psychotropic cannabinoid and that lab and animal evidence suggests CBD may act as an antioxidant, reduce inflammation, help skin moisturize, fight acne, help wounds heal, and have…
